biostudies-literatureUnknown8(9)Jo DHRetinoblastoma is the most common intraocular cancer in children, affecting 1/20,000 live births. Currently, children with retinoblastoma were treated with chemotherapy using drugs such as carboplatin, vincristine, and etoposide. Unfortunately, if conventional treatment fails, the affected eyes should be removed to prevent extension into adjacent tissues and metastasis. This study is to investigate the roles of L1 in adhesion-mediated proliferation and chemoresistance of retinoblastoma. L1 was differentially expressed in 30 retinoblastoma tissues and 2 retinoblastoma cell lines. Furthermore, the proportions of L1-positive cells in retinoblastoma tumors were negatively linked with the number of Flexner-Wintersteiner rosettes, a characteristic of differentiated retinoblastoma tumors, in eachOncotarget15441-15452https://www.ebi.ac.uk/biostudies/studies/S-EPMC5362498biostudies-literatureL1 increases adhesion-mediated proliferation and chemoresistance of retinoblastoma.PMC5362498Min JKYu YSCho YLLee KJo DHKim JHKim YJun HOfalseL1 increases adhesion-mediated proliferation and chemoresistance of retinoblastoma.Retinoblastoma is the most common intraocular cancer in children, affecting 1/20,000 live births. Currently, children with retinoblastoma were treated with chemotherapy using drugs such as carboplatin, vincristine, and etoposide. Unfortunately, if conventional treatment fails, the affected eyes should be removed to prevent extension into adjacent tissues and metastasis. This study is to investigate the roles of L1 in adhesion-mediated proliferation and chemoresistance of retinoblastoma. L1 was differentially expressed in 30 retinoblastoma tissues and 2 retinoblastoma cell lines. Furthermore, the proportions of L1-positive cells in retinoblastoma tumors were negatively linked with the number of Flexner-Wintersteiner rosettes, a characteristic of differentiated retinoblastoma tumors, in each2017-01-01T00:00:00Z2017 Feb2025-04-26T01:05:35.652Z2019-03-27T02:39:18ZS-EPMC53624982806146010.18632/oncotarget.14487